



SEQUENCE LISTING

<110> Vicari, Alain P.
Caux, Christophe
LaFace, Drake

<120> Chemokines as Adjuvants of Immune Response

<130> SF0896K US

<140> US 09/768,917
<141> 2001-01-24

<150> EP 0 974 357
<151> 1998-07-16

<160> 12

<170> PatentIn Ver. 2.1

<210> 1
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 1
atttcagcga tgttttcgac tc

JUN 18 2002

TECH CENTER 1600/2000

RECEIVED

<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 2
ggagaagcct gaggacttgt a

21

<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 3
gattacatcg gagacaacac c

21

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 4
tagtccaggc agaagagtgcg 20

<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 5
gctgccttgg gtgttgtatt t 21

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 6
agaggaggcag cagtgagcaa 20

<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 7
ttgctcctgg ctgctttg 18

<210> 8
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 8
accctccatg atgtgcaag 19

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 9
ctgctgggttc tctggacttc 20

```

<210> 10
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 10
cacactcaca ctcacacaca c 21

<210> 11
<211> 297
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(297)
<223>

<400> 11
atg aaa gtc tct gca gtg ctt ctg tgc ctg ctg ctc atg aca gca gct 48
Met Lys Val Ser Ala Val Leu Leu Cys Leu Leu Leu Met Thr Ala Ala
1 5 10 15

ttc aac ccc cag gga ctt gct cag cca gat gca ctc aac gtc cca tct 96
Phe Asn Pro Gln Gly Leu Ala Gln Pro Asp Ala Leu Asn Val Pro Ser
20 25 30

act tgc tgc ttc aca ttt agc agt aag aag atc tcc ttg cag agg ctg 144
Thr Cys Cys Phe Thr Phe Ser Ser Lys Lys Ile Ser Leu Gln Arg Leu
35 40 45

aag agc tat gtg atc acc acc agc agg tgt ccc cag aag gct gtc atc 192
Lys Ser Tyr Val Ile Thr Thr Ser Arg Cys Pro Gln Lys Ala Val Ile
50 55 60

ttc aga acc aaa ctg ggc aag gag atc tgt gct gac cca aag gag aag 240
Phe Arg Thr Lys Leu Gly Lys Glu Ile Cys Ala Asp Pro Lys Glu Lys
65 70 75 80

tgg gtc cag aat tat atg aaa cac ctg ggc cgaa gct cac acc ctg 288
Trp Val Gln Asn Tyr Met Lys His Leu Gly Arg Lys Ala His Thr Leu
85 90 95

aag act tga 297
Lys Thr

<210> 12

```

<211> 98

<212> PRT

<213> Homo sapiens

<400> 12

Met Lys Val Ser Ala Val Leu Leu Cys Leu Leu Leu Met Thr Ala Ala
1 5 10 15

Phe Asn Pro Gln Gly Leu Ala Gln Pro Asp Ala Leu Asn Val Pro Ser
20 25 30

Thr Cys Cys Phe Thr Phe Ser Ser Lys Lys Ile Ser Leu Gln Arg Leu
35 40 45

Lys Ser Tyr Val Ile Thr Thr Ser Arg Cys Pro Gln Lys Ala Val Ile
50 55 60

Phe Arg Thr Lys Leu Gly Lys Glu Ile Cys Ala Asp Pro Lys Glu Lys
65 70 75 80

Trp Val Gln Asn Tyr Met Lys His Leu Gly Arg Lys Ala His Thr Leu
85 90 95

Lys Thr